Ralph Buchert1, Andreas Kluge2, Livia Tossici-Bolt3, John Dickson4, Marcus Bronzel2, Catharina Lange5, Susanne Asenbaum6, Jan Booij7, L Özlem Atay Kapucu8, Claus Svarer9, Pierre-Malick Koulibaly10, Flavio Nobili11, Marco Pagani12,13, Osama Sabri14, Terez Sera15, Klaus Tatsch16, Thierry Vander Borght17, Koen Van Laere18, Andrea Varrone19, Hidehiro Iida20. 1. Department of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany. ralph.buchert@charite.de. 2. ABX-CRO advanced pharmaceutical services Forschungsgesellschaft m.b.H., Dresden, Germany. 3. Department of Medical Physics, University Hospital Southampton NHS Foundation Trust, Southampton, UK. 4. Institute of Nuclear Medicine, University College London Hospital NHS Foundation Trust, London, UK. 5. Department of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany. 6. Department of Nuclear Medicine, Medical University of Vienna, Vienna, Austria. 7. Department of Nuclear Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands. 8. Department of Nuclear Medicine, Faculty of Medicine, Gazi University, Ankara, Turkey. 9. Neurobiology Research Unit, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark. 10. Nuclear Medicine Department, Centre Antoine Lacassagne, University of Nice-Sophia Antipolis, Nice, France. 11. Department of Neuroscience (DINOGMI), Clinical Neurology Unit, University of Genoa, Genoa, Italy. 12. Institute of Cognitive Sciences and Technologies, CNR, Rome, Italy. 13. Department of Nuclear Medicine, Karolinska Hospital, Stockholm, Sweden. 14. Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany. 15. Department of Nuclear Medicine and Euromedic Szeged, University of Szeged, Szeged, Hungary. 16. Department of Nuclear Medicine, Municipal Hospital of Karlsruhe Inc, Karlsruhe, Germany. 17. Nuclear Medicine Division, Université catholique de Louvain, CHU Namur, IREC, Yvoir, Belgium. 18. Nuclear Medicine, University Hospital and K.U. Leuven, Leuven, Belgium. 19. Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. 20. National Cerebral and Cardiovascular Center - Research Institute, Osaka, Japan.
Abstract
PURPOSE: Quantitative estimates of dopamine transporter availability, determined with [(123)I]FP-CIT SPECT, depend on the SPECT equipment, including both hardware and (reconstruction) software, which limits their use in multicentre research and clinical routine. This study tested a dedicated reconstruction algorithm for its ability to reduce camera-specific intersubject variability in [(123)I]FP-CIT SPECT. The secondary aim was to evaluate binding in whole brain (excluding striatum) as a reference for quantitative analysis. METHODS: Of 73 healthy subjects from the European Normal Control Database of [(123)I]FP-CIT recruited at six centres, 70 aged between 20 and 82 years were included. SPECT images were reconstructed using the QSPECT software package which provides fully automated detection of the outer contour of the head, camera-specific correction for scatter and septal penetration by transmission-dependent convolution subtraction, iterative OSEM reconstruction including attenuation correction, and camera-specific "to kBq/ml" calibration. LINK and HERMES reconstruction were used for head-to-head comparison. The specific striatal [(123)I]FP-CIT binding ratio (SBR) was computed using the Southampton method with binding in the whole brain, occipital cortex or cerebellum as the reference. The correlation between SBR and age was used as the primary quality measure. RESULTS: The fraction of SBR variability explained by age was highest (1) with QSPECT, independently of the reference region, and (2) with whole brain as the reference, independently of the reconstruction algorithm. CONCLUSION: QSPECT reconstruction appears to be useful for reduction of camera-specific intersubject variability of [(123)I]FP-CIT SPECT in multisite and single-site multicamera settings. Whole brain excluding striatal binding as the reference provides more stable quantitative estimates than occipital or cerebellar binding.
PURPOSE: Quantitative estimates of dopamine transporter availability, determined with [(123)I]FP-CIT SPECT, depend on the SPECT equipment, including both hardware and (reconstruction) software, which limits their use in multicentre research and clinical routine. This study tested a dedicated reconstruction algorithm for its ability to reduce camera-specific intersubject variability in [(123)I]FP-CIT SPECT. The secondary aim was to evaluate binding in whole brain (excluding striatum) as a reference for quantitative analysis. METHODS: Of 73 healthy subjects from the European Normal Control Database of [(123)I]FP-CIT recruited at six centres, 70 aged between 20 and 82 years were included. SPECT images were reconstructed using the QSPECT software package which provides fully automated detection of the outer contour of the head, camera-specific correction for scatter and septal penetration by transmission-dependent convolution subtraction, iterative OSEM reconstruction including attenuation correction, and camera-specific "to kBq/ml" calibration. LINK and HERMES reconstruction were used for head-to-head comparison. The specific striatal [(123)I]FP-CIT binding ratio (SBR) was computed using the Southampton method with binding in the whole brain, occipital cortex or cerebellum as the reference. The correlation between SBR and age was used as the primary quality measure. RESULTS: The fraction of SBR variability explained by age was highest (1) with QSPECT, independently of the reference region, and (2) with whole brain as the reference, independently of the reconstruction algorithm. CONCLUSION: QSPECT reconstruction appears to be useful for reduction of camera-specific intersubject variability of [(123)I]FP-CIT SPECT in multisite and single-site multicamera settings. Whole brain excluding striatal binding as the reference provides more stable quantitative estimates than occipital or cerebellar binding.
Authors: Z Walker; D C Costa; R W H Walker; K Shaw; S Gacinovic; T Stevens; G Livingston; P Ince; I G McKeith; C L E Katona Journal: J Neurol Neurosurg Psychiatry Date: 2002-08 Impact factor: 10.154
Authors: I George Zubal; Michele Early; Olive Yuan; Danna Jennings; Kenneth Marek; John P Seibyl Journal: J Nucl Med Date: 2007-05-15 Impact factor: 10.057
Authors: Markus Wenzel; Fausto Milletari; Julia Krüger; Catharina Lange; Michael Schenk; Ivayla Apostolova; Susanne Klutmann; Marcus Ehrenburg; Ralph Buchert Journal: Eur J Nucl Med Mol Imaging Date: 2019-08-31 Impact factor: 9.236
Authors: Helen Schmitz-Steinkrüger; Catharina Lange; Ivayla Apostolova; Franziska L Mathies; Lars Frings; Susanne Klutmann; Sabine Hellwig; Philipp T Meyer; Ralph Buchert Journal: Eur J Nucl Med Mol Imaging Date: 2020-10-31 Impact factor: 9.236
Authors: John C Dickson; Livia Tossici-Bolt; Terez Sera; Jan Booij; Morten Ziebell; Silvia Morbelli; Susanne Assenbaum-Nan; Thierry Vander Borght; Marco Pagani; Ozlem L Kapucu; Swen Hesse; Koen Van Laere; Jacques Darcourt; Andrea Varrone; Klaus Tatsch Journal: EJNMMI Res Date: 2017-01-24 Impact factor: 3.138
Authors: Livia Tossici-Bolt; John C Dickson; Terez Sera; Jan Booij; Susanne Asenbaun-Nan; Maria C Bagnara; Thierry Vander Borght; Cathrine Jonsson; Robin de Nijs; Swen Hesse; Pierre M Koulibaly; Umit O Akdemir; Michel Koole; Klaus Tatsch; Andrea Varrone Journal: EJNMMI Phys Date: 2017-01-28
Authors: Silvia Morbelli; Giuseppe Esposito; Javier Arbizu; Henryk Barthel; Ronald Boellaard; Nico I Bohnen; David J Brooks; Jacques Darcourt; John C Dickson; David Douglas; Alexander Drzezga; Jacob Dubroff; Ozgul Ekmekcioglu; Valentina Garibotto; Peter Herscovitch; Phillip Kuo; Adriaan Lammertsma; Sabina Pappata; Iván Peñuelas; John Seibyl; Franck Semah; Livia Tossici-Bolt; Elsmarieke Van de Giessen; Koen Van Laere; Andrea Varrone; Michele Wanner; George Zubal; Ian Law Journal: Eur J Nucl Med Mol Imaging Date: 2020-05-09 Impact factor: 9.236
Authors: Jonathan C Taylor; Nicholas Vennart; Ian Negus; Robin Holmes; Oliver Bandmann; Christine Lo; John Fenner Journal: Nucl Med Commun Date: 2018-03 Impact factor: 1.690